Shares of Gilead Sciences (GILD) soar 13.5% premarket after the firm reports positive results...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Shares of Gilead Sciences (GILD) soar 13.5% premarket after the firm reports positive results from a 12-week study of its Hepatitis C treatment GS-7977.